Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT03319940 2025-11-19

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Phase 1 Active not recruiting

269 enrolled

Thoracic

Bites and Stings, Neoplasms, Small Cell Lung Carcinoma

NCT03792841 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Phase 1 Terminated

212 enrolled

Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT04609579 2024-01-30

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Phase 1 Terminated

27 enrolled

GastrointestinalGynecologicLymphoid

Bites and Stings, Lymphoma, Ovarian Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell

NCT00274742 2015-01-16

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Phase 1 Completed

76 enrolled 15 charts

Lymphoid

Bites and Stings, Lymphoma, Non-Hodgkin, Recurrence

NCT00635596 2015-01-13

MT110-101

Phase 1 Completed

65 enrolled

Bites and Stings

Clinical Trials

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

OASIS

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

ON-5001

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

MT110-101